[{"from": "human", "value": "Provide a description of this molecule. [C][C@H1][C][C@H1][Branch1][=Branch1][C][C][O][Ring1][=Branch1][N][C][=Branch1][C][=O][C][C@@][Branch1][=Branch1][N][=C][Ring1][#Branch1][N][Branch1][C][C][C][=C][Branch2][Ring1][#Branch2][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][N][C][=Branch1][C][=O][C][=C][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][#N][Cl]"}, {"from": "gpt", "value": "The molecule is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria. Plasmepsins are aspartyl proteases produced by the malaria parasite Plasmodium falciparum, and PMX is considered to be essential for parasite egress and invasion. UCB7362 is estimated to achieve a significant reduction in asexual blood-stage parasites. It has shown high potency in biochemical (IC50 = 7 nM), in vitro (P. falciparum 3D7 lactate dehydrogenase growth inhibition assay  IC50 = 10 nM), and in vivo (50 mg/kg dose in mice) studies."}]